Trial · NCT04309084
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
NCT04309084, Phase 1, Unknown, Celularity Incorporated
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma. Trials, record NCT04309084. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04309084
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
- NCT number
- NCT04309084
- Status
- Unknown
- Phases
- Phase 1
- Enrollment
- 29 participants, estimated
- Lead sponsor
- Celularity Incorporated
- Conditions
Multiple Myeloma, Neoplasm, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorder, Vascular Diseases, Cardiovascular Diseases, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Diseases, Antineoplastic Agents, Analgesics, Non-Narcotic, Analgesics, Sensory System Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs
- Interventions
- CYNK-001
- First posted
- 2020-03-16
- Last updated
- 2023-02-16
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose-Limiting Toxicity (DLT) | Up to 28 days | Safety Assessment of Dose-Limiting Toxicity (DLT) |
| Primary | Maximum Tolerated Dose (MTD) or Maximum Planned Dose (MPD) | Up to 28 days | Safety Assessment of MTD OR MPD |
| Primary | Adverse Events (AE) | Up to 12 months | Safety Assessment of AE's |
| Primary | Rate of Minimal Residual Disease (MRD) Negativity | Day 90-100 | Efficacy Assessment of MRD |
| Secondary | Minimal Residual Disease (MRD) Response | Day 90-100 | Efficacy Assessment of MRD |
| Secondary | Time to MRD Response | up to 12 months | Efficacy Assessment of MRD |
| Secondary | International Myeloma Working Group (IMWG) response | up to 12 months | Efficacy Assessment of response |
| Secondary | duration of clinical response | up to 12 months | Efficacy Assessment of response |
| Secondary | Progression-free survival | up to 12 months | Efficacy Assessment of response |
| Secondary | time to progression | up to 12 months | Efficacy Assessment of response |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 16908915 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04309084
GET https://conductscience.org/api/trials/v1/NCT04309084/registered